Vis enkel innførsel

dc.contributor.authorJensvoll, Hilde
dc.contributor.authorSeverinsen, Marianne T.
dc.contributor.authorHammerstrøm, Jens
dc.contributor.authorBrækkan, Sigrid Kufaas
dc.contributor.authorKristensen, Søren R.
dc.contributor.authorCannegieter, Suzanne C.
dc.contributor.authorBlix, Kristine
dc.contributor.authorTjønneland, Anne
dc.contributor.authorRosendaal, Frits Richard
dc.contributor.authorDziewiecka, Olga
dc.contributor.authorOvervad, Kim
dc.contributor.authorNæss, Inger Anne
dc.contributor.authorHansen, John-Bjarne
dc.date.accessioned2016-03-14T10:55:33Z
dc.date.available2016-03-14T10:55:33Z
dc.date.issued2015-09-16
dc.description.abstractBackground: Although venous thromboembolism (VTE) is a known common complication in cancer patients, there is limited knowledge on patient-related and cancer-specific risk factors in the general population. The Scandinavian Thrombosis and Cancer (STAC) Cohort was established by merging individual data from three large Scandinavian cohorts (The Tromsø Study, the second Nord-Trøndelag Health Study, and the Danish Diet, Cancer and Health Study). Here, we present the profile of the STAC cohort and provide age-specific incidence rates of VTE and cancer. <p>Methods: The STAC cohort includes 144,952 subjects aged 19–101 years without previous VTE or cancer. Baseline information collected in 1993–1997 included physical examination, self-administered questionnaires, and blood samples. Validated VTE events and cancer diagnoses were registered up to 2007–2012. <p>Results: There were 2,444 VTE events (1.4 per 1,000 person-years [PY]) during follow-up, and the incidence increased exponentially from 0.3 per 1,000 PY in subjects aged 20–29 years to 6.4 per 1,000 PY in subjects aged 80+. Overall, 51% of the VTE events were provoked, and cancer was the most common provoking factor (19%), followed by immobilization and surgery (both 15%). In total, 19,757 subjects developed cancer during follow-up (9.8 per 1,000 PY), and the 5-year age-specific incidence rates of cancer were coherent with corresponding rates from the Norwegian Cancer Registry. <p>Conclusion: The STAC cohort will provide a unique opportunity to explore the epidemiology and impact of genetic and environmental patient-related and cancer-specific risk factors for VTE in the general population.en_US
dc.descriptionThis article was published in the following Dove Press journal: Clinical Epidemiology and available at <a href=http://dx.doi.org/10.2147/CLEP.S84279>http://dx.doi.org/10.2147/CLEP.S84279</a>en_US
dc.identifier.citationClinical Epidemiology 2015, 7:401-410en_US
dc.identifier.cristinIDFRIDAID 1285529
dc.identifier.doi10.2147/CLEP.S84279
dc.identifier.issn1179-1349
dc.identifier.urihttps://hdl.handle.net/10037/8923
dc.identifier.urnURN:NBN:no-uit_munin_8492
dc.language.isoengen_US
dc.publisherDove Medical Pressen_US
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750en_US
dc.subjectvenous thromboembolismen_US
dc.subjectincidence ratesen_US
dc.subjectperson-yearsen_US
dc.subjectpulmonary embolismen_US
dc.subjectpopulation-based cohorten_US
dc.subjectprospectiveen_US
dc.subjectcanceren_US
dc.titleExisting data sources in clinical epidemiology: The Scandinavian Thrombosis and Cancer Cohorten_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel